Header Logo

Connection

John Zajecka to Pyrrolidines

Back to Details
This is a "connection" page, showing publications John Zajecka has written about Pyrrolidines.
John Zajecka
Connection Strength
0.172
Pyrrolidines
  1. Double-blind, placebo-controlled, proof-of-concept trial of a kappa-selective opioid receptor antagonist augmentation in treatment-resistant depression. Ann Clin Psychiatry. 2020 02; 32(4):18-26.
    View in: PubMed
    Score: 0.172
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.